What is the recommended starting dose, titration schedule, and maximum dose of guanfacine (Intuniv) for children and adolescents aged 6–17 years with attention‑deficit/hyperactivity disorder, and how should dosing be adjusted in moderate to severe hepatic impairment or significant renal disease?

Guanfacine Dosing for ADHD in Children and Adolescents (Ages 6–17 Years)

Starting Dose and Initial Administration

Start guanfacine extended-release at 1 mg once daily in the evening, regardless of body weight. 1, 2 Evening administration is strongly preferred because somnolence and sedation are the most common adverse effects, occurring in approximately 50–63% of patients, and nighttime dosing minimizes daytime functional impairment while potentially improving sleep onset. 1, 3

Titration Schedule

Increase the dose by 1 mg per week based on clinical response and tolerability. 1, 2 The target dose range is 0.05 to 0.12 mg/kg/day or 1 to 7 mg/day, with the weight-adjusted approach of approximately 0.1 mg/kg once daily serving as a practical guide. 1, 2

• Monitor ADHD symptoms systematically at each dose adjustment using parent and teacher reports. 1
• Expect 2–4 weeks before observing clinical benefits, unlike stimulants which work immediately—this delayed onset is a critical counseling point to prevent premature discontinuation. 1
• Most patients achieve optimal response at doses between 2–4 mg/day, though higher doses up to 7 mg/day may provide additional benefit in some adolescents if tolerated. 1, 4

Maximum Dose

The maximum recommended dose is 4 mg/day in most clinical contexts, though doses up to 7 mg/day have been studied and used. 1, 2 For adolescents weighing >70 kg, weight-adjusted dosing of 0.12 mg/kg may exceed 4 mg/day and can be considered if tolerated, as data suggest these higher weight-adjusted doses may provide additional clinical benefits. 4

Dosing Adjustments in Special Populations

Moderate to Severe Hepatic Impairment

Reduce the dose by 50% in patients with moderate to severe hepatic impairment. 2 Guanfacine is primarily metabolized via CYP3A4, and hepatic dysfunction significantly impairs clearance. 2

Significant Renal Disease

Reduce the dose by 50% in patients with significant renal impairment (CrCl <30 mL/min). 2 Guanfacine is excreted predominantly through the kidneys, and renal dysfunction increases drug accumulation. 2

Critical Cardiovascular Monitoring

• Obtain baseline blood pressure and heart rate before initiating guanfacine. 1, 2
• Monitor vital signs at each dose adjustment and periodically during maintenance therapy. 1, 2
• Expect modest decreases in blood pressure (1–4 mm Hg systolic and diastolic) and heart rate (1–2 bpm), which are generally mild and clinically insignificant in most patients, though 5–15% may experience more substantial decreases requiring closer monitoring. 1, 5
• Screen for personal or family history of cardiac conditions (Wolff-Parkinson-White syndrome, sudden death, hypertrophic cardiomyopathy, long QT syndrome) before starting treatment. 1

Discontinuation Protocol

Never abruptly stop guanfacine—taper by 1 mg every 3–7 days to avoid rebound hypertension. 1, 2, 6 Although guanfacine extended-release carries a lower risk of rebound hypertension compared to clonidine or immediate-release guanfacine, tapering remains essential for safety. 6

Common Adverse Effects and Management

• Somnolence/sedation (50–63% of patients): Most common during dose titration; typically mild to moderate and often resolves with continued treatment. 1, 3
• Headache (20.5%): Usually transient and dose-related. 1
• Fatigue (15.2%): Often improves after the first 2–4 weeks. 1
• Dry mouth, dizziness, irritability, abdominal pain: Generally mild to moderate. 1, 2

Position in Treatment Algorithm

Guanfacine is generally recommended as second-line treatment after stimulants due to smaller effect sizes (approximately 0.7 vs. 1.0 for stimulants). 1, 7 However, guanfacine should be considered first-line when:

• ADHD co-occurs with sleep disturbances, tic disorders, or oppositional symptoms. 1, 3
• The patient has substance use risk (guanfacine is non-controlled). 1
• Stimulants have failed, caused intolerable adverse effects, or are contraindicated. 1

FDA-Approved Adjunctive Therapy

Guanfacine extended-release is FDA-approved for adjunctive use with stimulants, allowing lower stimulant doses while maintaining efficacy and potentially reducing stimulant-related adverse effects such as insomnia or rebound symptoms. 1 This combination provides "around-the-clock" symptom coverage, as guanfacine's 24-hour duration extends beyond the typical 8–12 hour stimulant effect. 1

Age-Specific Precautions

• Approved for ages 6–17 years only. 1, 2, 5
• Do not use in children younger than 6 years—behavioral therapy is first-line for preschool-aged children (4–5 years). 1
• For elementary school-aged children (6–11 years), prescribe guanfacine together with evidence-based parent- and/or teacher-administered behavior therapy. 2

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase guanfacine levels; consider dose reduction and monitor closely. 1
• CYP3A4 inducers (e.g., rifampin, phenytoin): May decrease guanfacine levels; higher doses may be needed. 1
• CNS depressants (phenothiazines, barbiturates, benzodiazepines, alcohol): Additive sedative effects; use with caution. 1